Results 61 to 70 of about 105,814 (267)

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Redemptive benefit of atorvastatin in the risk factors of coronary artery disease [PDF]

, 2011
Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease ...
Jayaraman Gowri , Arumugam Vijaya Anand , Shanmugam Achiraman , Govindha Raj Archunan , Subramaniyam Kalavathy , Palanisamy Sampath Kumar , Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res.
core  

Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury

Journal of Neuroinflammation, 2017
Neuroinflammation is an important secondary injury mechanism that has dual beneficial and detrimental roles in the pathophysiology of traumatic brain injury (TBI).
Xin Xu, Weiwei Gao, Shiqi Cheng, Dongpei Yin, Fei Li, Yingang Wu, Dongdong Sun, Shuai Zhou, Dong Wang, Yongqiang Zhang, Rongcai Jiang, Jian-ning Zhang   +11 more
semanticscholar   +1 more source

Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3

Advanced Science, EarlyView.
In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang, Linghua Zeng, Kunkun Zou, Keying Lin, Fangting Yao, Jinglun Song, Shumeng Zhang, Hanshu Feng, Zhichao Yang, Chunlei Wang, Hongtao Diao, Xue Kong, Tengfei Pan, Joonki Kim, Tianqi Duo, Linqiang Li, Yu Bian   +16 more
wiley   +1 more source

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.
Nur Aini Hasan, Viskasari Pintoko Kalanjati, Kusuma Eko Purwantari, Abdurachman Abdurachman, Muhammad Miftahussurur   +4 more
doaj   +1 more source

Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease

Advanced Science, EarlyView.
This research identified cardiac amyloid pathology, neurotrophic factor depletion, and reduced myocardial nerve function in a transgenic model of cerebral amyloidosis (Tg2576), Aβ‐challenged cardiomyocytes, and in human AD heart tissue. These findings carry significant diagnostic and therapeutic implications, emphasizing the role of neuro‐signaling ...
Andrea Elia, Rebecca Parodi‐Rullan, Rafael Vazquez‐Torres, Ashley Carey, Huaqing Zhao, Sabzali Javadov, Silvia Fossati   +6 more
wiley   +1 more source

A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis

Arthritis & Rheumatology, 2019
Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients.
G. Kitas, P. Nightingale, J. Armitage, N. Sattar, J. Belch, D. Symmons, George Jill Deborah Hawys Shobna Rebecca Peter Ian Paul I Kitas Belch Symmons Williams Vasishta Storey Night, G. Kitas, J. Belch, D. Symmons, H. Williams, Shobna Vasishta, R. Storey, P. Nightingale, I. Bruce, P. Durrington, I. McInnes, N. Sattar, D. Situnayake, A. Struthers, G. Lowe, J. Armitage, K. Fox, D. Haskard, C. Doré, A. Bosworth, M. Frenneaux, C. Edwards, J. Emberson, D. Bax, S. Cobbe, D. Stott, R. Sturrock, P. Macfarlane, R. Klocke, T. Pullar, S. Knight, I. Rowe, Pradeep Kumar, N. Goodson, D. Mulherin, Micheal Brzeski, P. Gardiner, D. Walker, R. Callaghan, M. Allen, D. Mccarey, E. George, C. Deighton, B. Kirkham, L. Teh, R. Luqmani, K. Chakravarty, J. Nixon, S. Richards, D. Scott, Tony Woolf, P. Prouse, J. Packham, M. Davies, D. Delord, T. O’Neill, I. Pande, J. Harvie, R. Watts, E. Rankin, G. Papasavvas, P. Emery, A. Sinha, B. Dasgupta, P. Creamer, A. Zoma, D. Walsh, J. Van‐Laar, Nigel Capps, A. Cairns, C. Marguerie, Namita Kumar, R. Abernethy, M. Lillicrap, S. Ralston, R. Makadsi, N. Hopkinson, S. Tan, M. Akil, Y. Ahmad, M. Adler, M. Bukhari, Paul Sanders, E. Roussou, K. Binymin, Ala'a A Hassan, R. Hughes, D. O’Reilly, P. Sainsbury, R. Richmond, Magliano Malgorzata, M. Nisar, Ann McEntergart, D. Roy, J. Marks, M. Batley, F. Mckenna, M. Irani, H. Harris, A. Smyth, E. Tunn, A. Young, Joegi Thomas, F. Hall, T. Marshall, C. Rao, K. Baburaj, J. Dixey, N. Gendi, F. Birrell, G. Chelliah, A. Morgan, D. Fishman, S. Knights, D. Coady, Bill Smith, B. Harrison, S. Siebert, Anthony K. C. Chan, K. Putchakayala, A. Al-Ansari, A. Gough, S. Naz, D. Pyne, T. Mahmud, Y. Patel, A. Isdale   +132 more
semanticscholar   +1 more source

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Advanced Science, EarlyView.
This work introduces a study that identifies HMGCR as a novel target in TNBC and develops a light‐gated PROTAC nanomedicine. Upon irradiation, this agent selectively degrades HMGCR, reprogramming lipid metabolism to induce ferroptosis and potent antitumor immunity, thereby significantly enhancing photoimmunotherapy efficacy.
Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie, Zheni Xu, Yaying Wu, Xin Peng, Zhenjie Wang, Kun Chen, Xiaoyan Xin, Bing Zhang   +18 more
wiley   +1 more source

Effect of atorvastatin on high sensitivity c-reactive protein, pulmonary function, and quality of life in chronic obstructive pulmonary disease - an open-labeled randomized control trial

Archives of Medicine and Health Sciences, 2017
Objective: Beneficial effects of statins on chronic obstructive pulmonary disease (COPD) have been projected in many retrospective studies, but prospective studies were lacking.
Manisha Bisht, Jagdish Rawat
doaj   +1 more source

Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin

BMC Complementary Medicine and Therapies, 2023
Background Cardiovascular disease and cancer are the main causes of morbidity and mortality worldwide. Studies have shown that these two diseases may have some common risk factors.
Yu-qian Li, Lu-yao Li, Xue Yang, Qi-qi Lei, Liu-yan Xiang, Yuan-ru Wang, Si-meng Gu, Ya-jun Cao, Yan Pan, Lu Tie, Xue-jun Li   +10 more
doaj   +1 more source